Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 5
2005 4
2006 5
2007 5
2008 2
2009 3
2010 1
2011 1
2012 3
2014 6
2015 7
2016 10
2017 6
2018 7
2019 5
2020 7
2021 7
2022 7
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.
Lê H, Deforges J, Cutolo P, Lamarque A, Hua G, Lindner V, Jain S, Balloul JM, Benkirane-Jessel N, Quéméneur E. Lê H, et al. Among authors: lindner v. Front Immunol. 2024 Apr 18;15:1379613. doi: 10.3389/fimmu.2024.1379613. eCollection 2024. Front Immunol. 2024. PMID: 38698850 Free PMC article.
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X, Vano YA, Su X, Helleux A, Lindner V, Mouawad R, Spano JP, Rouprêt M, Compérat E, Verkarre V, Sun CM, Bennamoun M, Lang H, Barthelemy P, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: lindner v. Cell Rep Med. 2023 Nov 21;4(11):101287. doi: 10.1016/j.xcrm.2023.101287. Epub 2023 Nov 14. Cell Rep Med. 2023. PMID: 37967556 Free PMC article.
In vitro vascularized immunocompetent patient-derived model to test cancer therapies.
Lê H, Deforges J, Hua G, Idoux-Gillet Y, Ponté C, Lindner V, Olland A, Falcoz PE, Zaupa C, Jain S, Quéméneur E, Benkirane-Jessel N, Balloul JM. Lê H, et al. Among authors: lindner v. iScience. 2023 Sep 29;26(10):108094. doi: 10.1016/j.isci.2023.108094. eCollection 2023 Oct 20. iScience. 2023. PMID: 37860774 Free PMC article.
Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.
Nounsi A, Seitlinger J, Ponté C, Demiselle J, Idoux-Gillet Y, Pencreach E, Beau-Faller M, Lindner V, Balloul JM, Quemeneur E, Burckel H, Noël G, Olland A, Fioretti F, Falcoz PE, Benkirane-Jessel N, Hua G. Nounsi A, et al. Among authors: lindner v. Biomedicines. 2023 Jun 26;11(7):1824. doi: 10.3390/biomedicines11071824. Biomedicines. 2023. PMID: 37509464 Free PMC article.
Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.
Campedel L, Compérat E, Cancel-Tassin G, Varinot J, Pfister C, Delcourt C, Gobet F, Roumiguié M, Patard PM, Daniel G, Bigot P, Carrouget J, Eymerit C, Larré S, Léon P, Durlach A, Ruffion A, de Mazancourt ES, Decaussin-Petrucci M, Bessède T, Lebacle C, Ferlicot S, Robert G, Vuong NS, Philip M, Crouzet S, Matillon X, Mège-Lechevallier F, Lang H, Mouracade P, Lindner V, Gougis P, Cussenot O, Rouprêt M, Seisen T. Campedel L, et al. Among authors: lindner v. BJU Int. 2023 Nov;132(5):581-590. doi: 10.1111/bju.16129. Epub 2023 Aug 10. BJU Int. 2023. PMID: 37488983
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, Elaidi RT, Verkarre V, Sun CM, Chevreau C, Bennamoun M, Lang H, Tricard T, Fridman WH, Sautes-Fridman C, Su X, Plassard D, Keime C, Thibault-Carpentier C, Barthelemy P, Oudard SM, Davidson I, Malouf GG. Davidson G, et al. Among authors: lindner v. Cancer Res. 2023 Sep 1;83(17):2952-2969. doi: 10.1158/0008-5472.CAN-22-3034. Cancer Res. 2023. PMID: 37335139
A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Béraud C, Bidan N, Lassalle M, Lang H, Lindner V, Krucker C, Masliah-Planchon J, Potiron E, Lluel P, Massfelder T, Allory Y, Misseri Y. Béraud C, et al. Among authors: lindner v. Front Oncol. 2023 May 26;13:1130048. doi: 10.3389/fonc.2023.1130048. eCollection 2023. Front Oncol. 2023. PMID: 37305585 Free PMC article.
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG. Vokshi BH, et al. Among authors: lindner v. Nat Commun. 2023 May 26;14(1):3034. doi: 10.1038/s41467-023-38472-y. Nat Commun. 2023. PMID: 37236926 Free PMC article.
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Rouprêt M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: lindner v. Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133. Clin Cancer Res. 2023. PMID: 36374555
86 results